Literature DB >> 7558140

Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules.

J Hakulinen1, S Meri.   

Abstract

Protectin (CD59) is a glycolipid-anchored inhibitor of the membrane attack complex (MAC) of human complement (C) that protects blood cells, endothelial cells and various epithelial cells from C-mediated lysis. Because of its activities protectin is a candidate molecule for use in the treatment of paroxysmal nocturnal haemoglobinuria or conditions where MAC causes tissue damage. Soluble, phospholipid-free forms of protectin have been isolated from human urine and produced in recombinant form, but they have only a relatively weak C lysis-inhibiting activity. In the present study we have looked for functionally active protectin in human breast milk. Milk is rich in fat droplets, milk fat globules (MFG), that are enveloped in a plasma membrane derived from secretory cells of the mammary gland. The membranes of MFG contain a variety of glycoproteins expressed by the mammary epithelial cells. Both immunofluorescence and immunoblotting analysis demonstrated that protectin was strongly expressed on human MFG. In sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, MFG protectin (CD59M) appeared as distinct bands with apparent molecular weights of 19,000-23,000 MW, similar to protectin extracted from MCF7 breast carcinoma cells. CD59M in breast milk was functionally active and had a glycophospholipid anchor, as judged by its ability to incorporate into guinea-pig erythrocytes and inhibit their lysis by human complement. These results indicate that functionally active protectin becomes enriched in MFG and imply that secretion of glycophospholipid-anchored molecules, e.g. into cow milk and colostrum, could be exploited as a means of producing bioactive molecules that need to be targeted into cell membranes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558140      PMCID: PMC1383925     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

5.  Protein determination in membrane and lipoprotein samples: manual and automated procedures.

Authors:  M A Markwell; S M Haas; N E Tolbert; L L Bieber
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 6.  Anti-inflammatory properties of human milk.

Authors:  A S Goldman; L W Thorpe; R M Goldblum; L A Hanson
Journal:  Acta Paediatr Scand       Date:  1986-09

7.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

Authors:  S Schönermark; E W Rauterberg; M L Shin; S Löke; D Roelcke; G M Hänsch
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

8.  A method for isolation of milk fat globules.

Authors:  S Patton; G E Huston
Journal:  Lipids       Date:  1986-02       Impact factor: 1.880

9.  Isolation and characterization of a major glycoprotein from milk-fat-globule membrane of human breast milk.

Authors:  A Imam; D J Laurence; A M Neville
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

10.  Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.

Authors:  R L Ceriani; E W Blank
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

View more
  10 in total

1.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.

Authors:  Gloriane Schnabolk; Mee Keong Beon; Stephen Tomlinson; Bärbel Rohrer
Journal:  J Ocul Pharmacol Ther       Date:  2017-03-23       Impact factor: 2.671

3.  Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis.

Authors:  S Meri; T Lehto; C W Sutton; J Tyynelä; M Baumann
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

4.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

5.  A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Sonia Cantel; Amol Kavishwar; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

Review 6.  Inhibitors of complement activity in human breast-milk: a proposed hypothesis of their physiological significance.

Authors:  M O Ogundele
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

7.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

Review 8.  SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.

Authors:  Wei-Sheng Tien; Jun-Hong Chen; Kun-Pin Wu
Journal:  BMC Bioinformatics       Date:  2017-03-14       Impact factor: 3.169

9.  Molecular pathogenesis of human CD59 deficiency.

Authors:  Netanel Karbian; Yael Eshed-Eisenbach; Adi Tabib; Hila Hoizman; B Paul Morgan; Ora Schueler-Furman; Elior Peles; Dror Mevorach
Journal:  Neurol Genet       Date:  2018-10-26

10.  Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung Transplantation.

Authors:  Kevin Budding; Eduard A van de Graaf; Tineke Kardol-Hoefnagel; Johanna M Kwakkel-van Erp; Bart D Luijk; Erik-Jan D Oudijk; Diana A van Kessel; Jan C Grutters; C Erik Hack; Henderikus G Otten
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.